ArticleCureus2026
Disseminated Juvenile Xanthogranuloma in an Infant Requiring Systemic Therapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile xanthogranuloma (XGJ) is a generally benign non-Langerhans cell histiocytosis (non-LCH) that primarily affects infants and children. It typically presents as a single skin lesion. Disseminated and profuse forms remain rare and can pose diagnostic or therapeutic challenges. The classification of histiocytoses has recently evolved, incorporating disseminated XGJ into group "C" of non-LCH cutaneous histiocytoses. While the prognosis for isolated cutaneous forms is excellent, vigilance regarding potential associations (type 1 neurofibromatosis and juvenile myelomonocytic leukemia) and systemic complications remains essential. We report the case of a four-month-old infant presenting with a purely cutaneous disseminated form of XGJ, confirmed by histopathology and immunohistochemistry, which required systemic corticosteroid therapy due to the rapid spread of the lesions. This study involves a four-month-old infant with no significant family history who has been presenting with gradually progressive papular skin lesions for one month. Clinical examination revealed multiple umbilicated, yellowish-brown papulonodules scattered across the face, trunk, limbs, skin folds, genital mucosa, and scalp; a café-au-lait spot was detected on one limb. Dermoscopy revealed a characteristic "sunset" pattern. Histopathological and immunohistochemical analysis (CD68+, CD163+, CD1a-, CD34-, S100-) confirmed the diagnosis. The staging evaluation revealed no abnormalities. After three months of simple monitoring, the extensive spread of the lesions prompted the initiation of oral corticosteroid therapy (1 mg/kg/day), resulting in partial regression at six weeks. Disseminated XGJ in infants remains a rare condition. Although the course is most often self-limiting, justifying an initial conservative approach, certain extensive forms may require systemic treatment. The dermatologist plays a central role in diagnosis, based on a combination of clinical, dermoscopic, histopathological, and immunohistochemical findings, and in the multidisciplinary decision-making regarding treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.